NYSE:SLB
NYSE:SLBEnergy Services

SLB (NYSE:SLB) Valuation in Focus After Q3 Earnings Beat and ChampionX Boost

SLB (NYSE:SLB) just reported third-quarter earnings that came in ahead of analyst expectations, due in part to stronger North American revenue and the recent ChampionX acquisition. Although the business delivered a clear profit beat, investor caution is evident as oil prices remain volatile and clients are still trimming drilling budgets. These dynamics are influencing how markets respond to SLB's otherwise strong results. See our latest analysis for SLB. This latest update comes on the heels...
NasdaqGM:MRUS
NasdaqGM:MRUSBiotechs

Merus (MRUS): Reviewing Valuation Following Strong Share Price Gains

Merus (MRUS) stock has delivered an impressive run, up 39% over the past month and 124% year-to-date. Investors are taking note because these gains come amid continued positive momentum for the biotech as the sector evolves. See our latest analysis for Merus. Merus’s 1-month share price return of 39% shows serious momentum, but that’s only part of the story. The total shareholder return comes in at over 83% for the past year, with five-year holders seeing gains north of 600%. That level of...
NYSE:CR
NYSE:CRMachinery

Crane (CR): Assessing Valuation Following Declining Sales and Slower Organic Revenue Growth

Crane (CR) has come under pressure following recent news that the company is experiencing declining sales and disappointing organic revenue growth. These operational headwinds raise important questions for investors evaluating the stock’s current outlook. See our latest analysis for Crane. Despite recent worries over declining sales, Crane’s 24.14% year-to-date share price return stands out. Its three-year total shareholder return of 197.40% highlights robust long-term gains, even as momentum...
NasdaqCM:CORT
NasdaqCM:CORTPharmaceuticals

Corcept Therapeutics (CORT) Is Up 9.9% After Relacorilant–Nab-Paclitaxel Phase 3 Success in Ovarian Cancer

Corcept Therapeutics recently presented new, positive Phase 3 ROSELLA trial data at the ESMO 2025 Annual Meeting, showing that relacorilant plus nab-paclitaxel improved progression-free survival for patients with platinum-resistant ovarian cancer, including those previously treated with PARP inhibitors. The findings suggest relacorilant may offer a clinically meaningful benefit for a particularly high-risk patient group where chemotherapy resistance is a significant challenge. We'll examine...
NasdaqGM:TVTX
NasdaqGM:TVTXBiotechs

FILSPARI’s New Clinical Data Might Change the Case for Investing in Travere Therapeutics (TVTX)

Earlier this month, Travere Therapeutics announced it would present 11 abstracts, including a late-breaking poster, showcasing new data on FILSPARI at the American Society of Nephrology Kidney Week 2025 in Houston, TX, with real-world and late-breaking clinical results highlighting FILSPARI’s ability to lower proteinuria and potentially preserve kidney function in rare kidney diseases. The late-breaking data from the DUPLEX and SPARTAN studies suggest FILSPARI may offer consistent benefits...
NYSE:AFL
NYSE:AFLInsurance

Aflac (AFL): Evaluating Valuation Ahead of Next Month’s Earnings and Forecasted Profit Dip

Aflac (AFL) is drawing attention as it prepares to release its third-quarter results next month. Investors are watching closely, with forecasts pointing to a sharp, temporary drop in profits followed by a possible rebound in 2026. See our latest analysis for Aflac. Aflac’s share price has held steady at $108.77, gradually pushing higher with a 5.9% climb over the past 90 days as investors weigh the mixed outlook from its upcoming earnings update and recent community initiatives like the My...
NYSE:GRND
NYSE:GRNDInteractive Media and Services

Grindr (GRND): Assessing Valuation After Recent Share Price Declines

Grindr (GRND) shares have seen a sharp drop over the past month, declining nearly 20%. The slide has deepened with a 34% fall in the past 3 months. Investors may be wondering what is driving the downturn. See our latest analysis for Grindr. Grindr's share price has taken a noticeable hit lately, which comes on the heels of a rough few months. However, it is worth putting the pullback in context. While momentum has clearly faded recently, especially with a 1-month share price return of nearly...
NasdaqGS:ONB
NasdaqGS:ONBBanks

A Look at Old National Bancorp’s (ONB) Valuation Following Sector Credit Quality Concerns

Regional bank stocks are feeling the heat after two lenders reported substantial loan losses and collateral issues, which has raised fresh questions about industrywide credit quality. Old National Bancorp (ONB) is among the banks seeing shares pressured by these developments. See our latest analysis for Old National Bancorp. Old National Bancorp’s share price came under pressure alongside other regional banks after several industry peers reported loan charge-offs and collateral issues,...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Gilead Sciences (GILD): Assessing Valuation After Major Trodelvy Breast Cancer Breakthrough and HIV Advances

Gilead Sciences (GILD) has been drawing attention after releasing promising Phase 3 results for Trodelvy. The results show a marked extension in progression-free survival among metastatic triple-negative breast cancer patients. The company also highlighted advances in HIV prevention and treatment. See our latest analysis for Gilead Sciences. All this news comes as Gilead’s share price has surged by nearly 34% year-to-date, with momentum clearly building on the back of major new clinical data,...
NasdaqGS:MSTR
NasdaqGS:MSTRSoftware

Is MSTR’s Record Bitcoin-Driven Profits a Strength or a Risk to Its Balance Sheet Strategy?

In October 2025, Strategy Inc (formerly MicroStrategy) faced significant volatility due to its heavy exposure to Bitcoin price movements and industry-wide shifts, as the company reported record GAAP profits driven by unrealized Bitcoin gains and continued to meet key milestones for index inclusion. This period has seen a wave of new Bitcoin treasury companies entering the sector and heightened debate about the risks of leveraging digital assets for corporate balance sheets, reflecting...
NasdaqGS:AVGO
NasdaqGS:AVGOSemiconductor

Will Broadcom's (AVGO) OpenAI Alliance Redefine Its Role in AI Data Center Infrastructure?

Earlier this month, OpenAI announced a multi-year collaboration with Broadcom to co-develop and deploy 10 gigawatts of custom AI accelerators starting in 2026, leveraging Broadcom’s advanced networking and chip design expertise. This partnership positions Broadcom as a key hardware provider for large-scale AI infrastructure, highlighting the critical role of Ethernet networking and custom silicon in powering future AI data centers. We'll examine how Broadcom's deeper relationship with OpenAI...
NYSE:AORT
NYSE:AORTMedical Equipment

How Positive AMDS Trial Results Could Shape Artivion's (AORT) Clinical and Market Trajectory

Artivion recently announced the presentation of positive 30-day data from its AMDS PERSEVERE and PROTECT clinical trials at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting in Copenhagen, which showed reduced adverse events and mortality for patients with acute aortic dissection treated with the AMDS hybrid prosthesis. The results highlighted that 83% of high-risk patients avoided major gastrointestinal complications, outcomes which support the AMDS device's evidence...
NasdaqGS:PHVS
NasdaqGS:PHVSPharmaceuticals

Pharvaris (PHVS): Analyst Upgrades and Institutional Interest Spark Fresh Look at Valuation

Pharvaris (PHVS) is getting attention after a wave of analyst upgrades and new coverage, as well as a "Moderate Buy" consensus from several brokerages. Recent moves by institutional investors indicate increasing interest in the company. See our latest analysis for Pharvaris. Pharvaris has enjoyed strong momentum recently, with a share price jump of nearly 12% in the last day alone. This adds to this year’s impressive 27% share price return. Positive analyst attention and increased...
NasdaqGS:MLKN
NasdaqGS:MLKNCommercial Services

How MillerKnoll’s (MLKN) ESOP Share Offering Could Shape Its Investment Story

On October 17, 2025, MillerKnoll, Inc. filed a shelf registration for up to 3,400,000 shares of common stock valued at approximately US$56.92 million, specifically for its Employee Stock Ownership Plan (ESOP). This move signals a significant step in the company's approach to corporate finance and employee ownership, with potential implications for both capital structure and workforce engagement. We'll explore how the ESOP-related share offering could influence MillerKnoll's investment...
NYSE:KMI
NYSE:KMIOil and Gas

Kinder Morgan (KMI): Exploring Valuation Following Jefferies' Bullish Outlook on US Natural Gas Growth

Jefferies has just initiated coverage on Kinder Morgan (NYSE:KMI), highlighting how rising demand for US natural gas and a sizable projects backlog could drive the company’s earnings growth through 2030. This outlook is sparking fresh investor interest. See our latest analysis for Kinder Morgan. Kinder Morgan’s latest buzz comes against a backdrop of steady momentum. While the share price has been fairly stable this year, its 12-month total shareholder return stands out at 16.2%. The...
NYSE:AGX
NYSE:AGXConstruction

Argan (AGX): Assessing Valuation Following Strong Q2 Earnings, Analyst Upgrade, and AI Power Demand Optimism

Argan (AGX) has caught investor attention after reporting second quarter earnings that topped expectations. The update was complemented by an analyst upgrade, along with growing optimism around future demand from AI-related power needs. See our latest analysis for Argan. Argan’s share price has soared in recent months, fueled by standout Q2 earnings, a surge of optimism over AI-driven growth in the power sector, and a recent dividend boost. The stock’s 1-month share price return of 11.4% is...
NasdaqGS:IBOC
NasdaqGS:IBOCBanks

Did a Dividend Hike and Analyst Optimism Just Shift International Bancshares' (IBOC) Investment Narrative?

International Bancshares recently raised its semi-annual dividend from $0.66 to $0.70 per share and received reaffirmed "buy" ratings from analysts including Weiss Ratings. This dividend hike comes alongside increased investment from institutional firms, reflecting ongoing confidence in the company's outlook. We'll explore how International Bancshares' dividend increase may influence its long-term investment story for shareholders. This technology could replace computers: discover 26 stocks...
NasdaqGS:WAFD
NasdaqGS:WAFDBanks

A Fresh Look at WaFd (WAFD) Valuation After Recent Share Price Trends

WaFd (WAFD) shares have moved only slightly over the past day, with modest volatility over the past month as well. Investors may be watching closely to see how ongoing performance trends shape upcoming results. See our latest analysis for WaFd. Looking beyond the recent modest volatility, WaFd’s share price has trended lower this year, with a 1-year total shareholder return of -14.54%. The longer-term picture tells a different story, thanks to solid gains over five years, though current...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

Apellis Pharmaceuticals (APLS): Assessing Valuation Following Wells Fargo’s Upgrade and Renewed Analyst Confidence

Shares of Apellis Pharmaceuticals (APLS) drew attention recently after Wells Fargo shifted its rating to “Overweight,” reflecting a stronger outlook for the company. Multiple brokerage firms also voiced a positive consensus, which stirred investor interest. See our latest analysis for Apellis Pharmaceuticals. Momentum around Apellis Pharmaceuticals has picked up following the analyst upgrade, as optimism on both its product expansion efforts and strengthened financial performance gained...
NYSE:WRB
NYSE:WRBInsurance

Will Slower Revenue Growth and Higher EPS Guidance Change W. R. Berkley's (WRB) Narrative?

Property casualty insurer W. R. Berkley reported its third-quarter earnings on Monday, with analysts expecting revenue to reach US$3.71 billion, reflecting 9% year-on-year growth, though slower than the previous year's pace. Despite the projected easing in revenue growth, analysts forecast an 18.3% increase in earnings per share, highlighting a continued focus on profitability amid broader market uncertainty related to potential trade and tax policy changes. We’ll assess how analysts’...
NYSE:STEL
NYSE:STELBanks

Stellar Bancorp (STEL): Assessing Valuation in Light of Fresh Regional Bank Loan Worries

Several regional banks revealed fresh loan problems this week, sparking new concerns about credit quality and exposure across the industry. Stellar Bancorp (STEL) found itself included in the conversation as investors grew more cautious. See our latest analysis for Stellar Bancorp. Stellar Bancorp’s share price has pulled back around 5% in the past month, with sentiment across regional banks dented by industry-wide worries over commercial real estate exposure and credit quality. However, the...
NYSE:COTY
NYSE:COTYPersonal Products

The Bull Case For Coty (COTY) Could Change Following $900 Million Debt Refinancing With New Credit Provisions

Earlier this month, Coty Inc. completed a private offering of US$900 million in 5.600% senior notes due 2031, with proceeds earmarked to refinance existing senior secured notes maturing in 2026. This refinancing move introduces new ratings-based guarantees and collateral provisions, potentially impacting Coty’s financial flexibility and obligations depending on future credit ratings. We'll examine how this major debt refinancing initiative could impact Coty’s investment narrative and future...
NYSE:DD
NYSE:DDChemicals

DuPont (DD): Evaluating Valuation Following Major SK hynix Deal in Next-Gen Semiconductor Materials

DuPont de Nemours (DD) just made headlines as its Electronics segment, Qnity, entered a Memorandum of Understanding with SK hynix to supply advanced polishing pads for semiconductor fabrication. This new agreement positions DuPont as a key partner in supporting next-generation chip and AI production. See our latest analysis for DuPont de Nemours. DuPont de Nemours’ recent momentum has been encouraged by growth in its Electronics segment and new product launches, but the share price tells a...
NYSE:EOG
NYSE:EOGOil and Gas

EOG Resources (EOG): Evaluating Current Valuation After Recent Share Price Decline

EOG Resources (EOG) has seen its shares under pressure lately, slipping about 9% over the past month. Investors are keeping an eye on recent performance trends and considering where potential value might emerge in the current environment. See our latest analysis for EOG Resources. Over the past year, EOG Resources has experienced a notable loss of momentum, with a 1-year total shareholder return of -12.6% and shares recently closing at $106.22. While strong five-year gains remain, recent...